Celemics

Celemics CROIC

The Cash Return on Invested Capital (CROIC) of Celemics (331920.KQ) as of Oct 24, 2026 is -16.35 %. In the previous year, Cash Return on Invested Capital (CROIC) was -1.82 % — a change of 800.28% (lower).

CROIC

-16.35 %

YoY

800.28%

Last updated:

Cash Return on Invested Capital (CROIC) of Celemics is 2025 -16.35 % . Cash Return on Invested Capital (CROIC) of Celemics was 2024 -1.82 % . It decreases by 800.28% lower compared to the previous year.

The Celemics CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
36.14 KRW
Jan 1, 2019
-90.53 KRW
Jan 1, 2020
-16.93 KRW
Jan 1, 2021
-15.32 KRW
Jan 1, 2022
-24.12 KRW
Jan 1, 2023
-28.93 KRW
Jan 1, 2024
-1.82 KRW
Jan 1, 2025
-16.35 KRW
The Celemics CROIC history
YEARCROICYoY
-16.35 %+800.28%
-1.82 %-93.72%
-28.93 %+19.95%
-24.12 %+57.49%
-15.32 %-9.56%
-16.93 %-81.29%
-90.53 %-350.46%
36.14 %-86.46%
266.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Cash Return on Invested Capital (CROIC) of Celemics is -16.35 % in 2025.

Cash Return on Invested Capital (CROIC) of Celemics changed from -1.82 % to -16.35 %, representing a 800.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Celemics since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Celemics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Celemics

All Key Metrics — Celemics